A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

NCT00473889 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

253

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.

Conditions

Stage IIIB or IV Non-Small Cell Lung Cancer

Interventions

DRUG: vorinostat
DRUG: Comparator: paclitaxel
DRUG: Comparator: carboplatin
DRUG: Comparator: placebo

Sponsor

Merck Sharp & Dohme LLC